[Vascular prevention after cerebral infarct or transient ischemic accident. Recommendations. March, 2008].
Zuber
M
M
Service de neurologie et neurovasculaire, Groupe hospitalier Paris Saint-Joseph, Paris, France. mzuber@hpsj.fr
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000069059:Atorvastatin; D001921:Brain / Q000098:blood supply* / Q000503:physiopathology*; D002544:Cerebral Infarction / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology*; D002560:Cerebrovascular Circulation / Q000502:physiology; D003327:Coronary Disease / Q000188:drug therapy / Q000517:prevention & control*; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000453:epidemiology / Q000517:prevention & control*; D002546:Ischemic Attack, Transient / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012307:Risk Factors; D013997:Time Factors
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D010975:Platelet Aggregation Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin